Evidence map›Paper›PMID 28117404›Full record

ArticleScientific reports2017

ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signaling.

Xiaoming Li, Fei Wang, Min Xu, Philip Howles, Patrick Tso

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. HDL metabolism and function in diabetes mellitus.Nature reviews. Endocrinology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Frontiers in pharmacology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Effects of ibuprofen in the ZDF rat model of type 2 diabetes.Journal of food and drug analysis · 2024
    Article
  12. Article
  13. Article
  14. From fasting to fat reshaping: exploring the molecular pathways of intermittent fasting-induced adipose tissue remodeling.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Inhibition of Vascular Inflammation by Apolipoprotein A-IV.Frontiers in cardiovascular medicine · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xiaoming LiNational Local Joint Engineering Research Centre of Biodiagnostics and Biotherapy, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, 157 W 5th Rd, Xincheng, Xi'an 710004, China.
Fei WangDepartment of Pathology and Laboratory Medicine, Metabolic Diseases Institute, University of Cincinnati, 2180 E. Galbraith Road, Cincinnati 45237-0507, USA.
Min XuDepartment of Pathology and Laboratory Medicine, Metabolic Diseases Institute, University of Cincinnati, 2180 E. Galbraith Road, Cincinnati 45237-0507, USA.
Philip HowlesDepartment of Pathology and Laboratory Medicine, Metabolic Diseases Institute, University of Cincinnati, 2180 E. Galbraith Road, Cincinnati 45237-0507, USA.
Patrick TsoDepartment of Pathology and Laboratory Medicine, Metabolic Diseases Institute, University of Cincinnati, 2180 E. Galbraith Road, Cincinnati 45237-0507, USA.
University of Cincinnati · USSecond Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

LIPID, LIPOPROTEIN, AND GLUCOSE METABOLISM COREU24DK059630 · NIDDK · UNIVERSITY OF CINCINNATI · PI TSO, PATRICK · 2001 to 2015
$12.9M
Lipid profile, lipoprotein and apolipoprotein composition, and intestinal fat absorption efficiency in germ-free and conventional miceU2CDK059630 · NIDDK · UNIVERSITY OF CINCINNATI · PI LIU, MIN · 2016 to 2021
$4.9M
Functional & molecular study of intetinal cholesterol transporters & absorptionR01DK076928 · NIDDK · UNIVERSITY OF CINCINNATI · PI TSO, PATRICK · 2007 to 2011
$1.6M
Gut mucosal mast cells are activated by fat absorption: physiology and mechanismR01DK092138 · NIDDK · UNIVERSITY OF CINCINNATI · PI TSO, PATRICK · 2011 to 2015
$1.5M
NIDDK NIH HHS R01 DK076928NIDDK NIH HHS R01 DK092138NIDDK NIH HHS U24 DK059630NIDDK NIH HHS U2C DK059630
6 · The paper itself

Abstract

Insulin resistance is a risk factor for type 2 diabetes mellitus. We investigated the effect of ApoA-IV on glucose uptake in the adipose and muscle tissues of mice and cultured 3T3-L1 adipocytes. We found that treatment with ApoA-IV lowered fasting blood glucose in both WT and diabetic KKAy mice by increasing glucose uptake in cardiac muscle, white adipose tissue, and brown adipose tissue through a mechanism that was partially insulin independent. Cell culture experiments showed that ApoA-IV improved glucose uptake in adipocytes in the absence of insulin by upregulating GLUT4 translocation by PI3K mediated activation of Akt signaling pathways. Considering our previous finding that ApoA-IV treatment enhanced pancreatic insulin secretion, these results suggests that ApoA-IV acts directly upon adipose tissue to improve glucose uptake and indirectly via insulin signaling. Our findings warrant future studies to identify the receptor for ApoA-IV and the downstream targets of PI3K-Akt signaling that regulate glucose uptake in adipocytes as potential therapeutic targets for treating insulin resistance.

Indexed as

Insulin ResistanceSignal Transduction3T3-L1 CellsAdipocytesAdipose TissueAndrostadienesAnimalsApolipoproteins ABlood GlucoseDiabetes Mellitus, ExperimentalEnzyme ActivationGlucoseGlucose Transporter Type 4MaleMiceMice, Inbred C57BLAndrostadienesapolipoprotein A-IVApolipoproteins ABlood GlucoseGlucoseGlucose Transporter Type 4Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktWortmannin

Identifiers

PMID28117404
PMCPMC5259790
OpenAlexW2582611686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.